AREVA Med

decorative

About AREVA Med

AREVA Med is an AREVA subsidiary created in 2009 to develop innovative therapies to fight cancer.

decorative

Nuclear Medicine

Learn more about nuclear medicine and targeted alpha therapy (TAT) with lead-212, and about our ongoing research.

decorative

Clinical Trials

AREVA Med launched the first Phase 1 clinical trial of lead-212       (patient enrollment completed in 2014).

decorative

News & Materials

Read about the latest news and events, watch a video, or download our brochure.

decorative

Macrocyclics

Macrocyclics, an AREVA Med company, is the global leader in chelating agent technologies for medicine.

Latest News

RadioMedix and AREVA Med - SBIR NCI Contract awarded to develop targeted alpha-emitter therapy of neuroendocrine tumors with lead-212

11/01/2016

RadioMedix and AREVA Med - SBIR NCI Contract awarded to develop targeted alpha-emitter therapy of neuroendocrine tumors with lead-212

Read more
AREVA Med appoints Julien Dodet as new Chief Executive Officer

08/01/2016

AREVA Med appoints Julien Dodet as new Chief Executive Officer

Read more
Nordic Nanovector and AREVA Med to investigate potential of  lead-212 conjugated anti-CD37 antibody for treating leukaemias

06/28/2016

Nordic Nanovector and AREVA Med to investigate potential of  lead-212 conjugated anti-CD37 antibody for treating leukaemias

Read more
Contact

For more information about AREVA Med, please contact:
Alison Tise
Tel.: + 1 (301) 841-1673

Contact

For more information about Macrocyclics, please contact:

Garry Kiefer

Tel.: + 1 (972) 250-2248

CEO Cancer Gold Standard
decorative

AREVA Med receives CEO Cancer Gold Standard accreditation

Twitter
decorative

Follow @AREVAmed on

Linked In
decorative

Follow AREVA Med on